Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Recruiting · NCT05342493 · Observational (researchers observe without assigning treatment) · Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
What this trial is about
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Exclusion criteria
- patients with a known hypersensitivity to components of AJOVY
Where it is running
1 location listed.
- Pharmacovigilance Department - Osaka, Japan